Template:Cs1 config Template:Main other <templatestyles src="Infobox drug/styles.css"/> {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

@@@ (See parameter list). This message only shows in Preview, it will not show after you do Template:Button.

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=132112CC(C)Sc1cc(OC)c(cc1OC)CCN1S/C13H21NO2S/c1-9(2)17-13-8-11(15-3)10(5-6-14)7-12(13)16-4/h7-9H,5-6,14H2,1-4H3HDYZSVKZKDPLDT-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= Oral<ref name="CitePiHKAL" />Serotonin; 5-HT2 receptor agonist; Serotonergic psychedelic; HallucinogenNone | _legal_data=

| _other_data=2-{2,5-Dimethoxy-4-[(propan-2-yl)sulfanyl]phenyl}ethan-1-amine

| _image_0_or_2 = 2C-T-4 2DACS.svg2C-T-4-3d-sticks.png | _image_LR =

| _datapage = 2C-T-4 (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all= | _ATC_prefix_supplemental=None | _has_EMA_link = | CAS_number=207740-25-8 | PubChem=44350070 | ChemSpiderID=21106232 | ChEBI= | ChEMBL=338259 | DrugBank= | KEGG=C22735 | _hasInChI_or_Key={{#if:1S/C13H21NO2S/c1-9(2)17-13-8-11(15-3)10(5-6-14)7-12(13)16-4/h7-9H,5-6,14H2,1-4H3HDYZSVKZKDPLDT-UHFFFAOYSA-N |yes}} | UNII=558WSD71D4 | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=477216693}}

2C-T-4, also known as 4-isopropylthio-2,5-dimethoxyphenethylamine, is a psychedelic phenethylamine of the 2C family.<ref name="CitePiHKAL" /><ref name="ShulginManningDaley2011">Template:Cite book</ref> It was first synthesized by Alexander Shulgin and is used as entheogenic recreational drug.<ref name="CitePiHKAL" />

EffectsEdit

2C-T-4 produces psychedelic and entheogenic effects that develop slowly and can last 12 to 18Template:Nbsphours.<ref name="CitePiHKAL" /> While users may experience virtually no effects for the first hour after ingestion, results vary drastically between individuals and range from hallucination and euphoria to intense sickness and anxiety.<ref name="CitePiHKAL">Template:CitePiHKAL</ref> Shulgin devoted a chapter in the first part of his book PiHKAL to this compound, describing an intense "plus-four" psychedelic experience mediated by a twelve milligram dose.

InteractionsEdit

Template:See also

2C drugs are metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B.<ref name="DeanStellpflugBurnett2013">Template:Cite journal</ref><ref name="TheobaldMaurer2007">Template:Cite journal</ref> Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C drugs.<ref name="DeanStellpflugBurnett2013" /><ref name="TheobaldMaurer2007" /><ref name="HalmanKongSarris2024">Template:Cite journal</ref> This may result in overdose and serious toxicity.<ref name="HalmanKongSarris2024" /><ref name="DeanStellpflugBurnett2013" />

PharmacologyEdit

Template:Nowrap
Target Affinity (Ki, nM)
5-HT1A 470–916
5-HT1B Template:Abbr
5-HT1D Template:Abbr
5-HT1E Template:Abbr
5-HT1F Template:Abbr
5-HT2A 27.9–54 (Ki)
5.5–220 (Template:Abbrlink)
56–87% (Template:Abbrlink)
5-HT2B Template:Abbr (Ki)
63–160 (Template:Abbr)
68–75% (Template:Abbr)
5-HT2C 180–295 (Ki)
Template:Abbr (Template:Abbr)
Template:Abbr (Template:Abbr)
5-HT3 Template:Abbr
5-HT4 Template:Abbr
5-HT5A Template:Abbr
5-HT6 Template:Abbr
5-HT7 Template:Abbr
α1A 11,000
α1B, α1D Template:Abbr
α2A 130–217
α2B, α2C Template:Abbr
β1β3 Template:Abbr
D1 20,000
D2 16,000
D3 19,000
D4, D5 Template:Abbr
H1 >25,000
H2H4 Template:Abbr
M1M5 Template:Abbr
I1 Template:Abbr
σ1, σ2 Template:Abbr
Template:Abbrlink 2,337–4,500 (Ki) (mouse)
19–53 (Ki) (rat)
3,700 (Template:Abbr) (mouse)
83 (Template:Abbr) (rat)
>30,000 (Template:Abbr) (human)
51% (Template:Abbr) (mouse)
67% (Template:Abbr) (rat)
Template:Abbrlink >30,000 (Ki)
113,000 (Template:Abbrlink)
Template:Abbr (Template:Abbr)
Template:Abbrlink 17,000 (Ki)
134,000 (Template:Abbr)
Template:Abbr (Template:Abbr)
Template:Abbrlink >30,000 (Ki)
294,000 (Template:Abbr)
Template:Abbr (Template:Abbr)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: <ref name="PDSPKiDatabase">{{#invoke:citation/CS1|citation CitationClass=web

}}</ref><ref name="RickliLuethiReinisch2015">Template:Cite journal</ref><ref name="LuethiTrachselHoener2018">Template:Cite journal</ref><ref name="SimmlerBuchyChaboz2016">Template:Cite journal</ref>

2C-T-4 acts as a serotonin 5-HT2 receptor agonist, including of the serotonin 5-HT2A receptor.<ref name="LuethiTrachselHoener2018" /><ref name="RickliLuethiReinisch2015" /> The mechanism that produces 2C-T-4's hallucinogenic and entheogenic effects has not been specifically established, however it is most likely to result from 5-HT2A receptor activation in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.

ChemistryEdit

2C-T-4 is the 2-carbon homolog of Aleph-4. The full chemical name is 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]-ethanamine. The drug has structural and pharmacodynamic properties similar to 2C-T-7 and 2C-T-19.Template:Citation needed

HomologueEdit

File:Psi-2C-T-4.png
Ψ-2C-T-4, the homologue of 2C-T-4.

2C-T-4 has a homologue, the structural isomer Ψ-2C-T-4 (2,6-dimethoxy-4-(i)-propylthiophenethylamine). This compound was tested by Alexander Shulgin at a dose of 12 mg.

At this dosage its duration was very short and it produced few effects, however based on the research into the better characterized compound Ψ-DOM, the potency of Ψ-2C-T-4 is likely to be around 1/3 that of 2C-T-4 itself, so a more effective dosage of Ψ-2C-T-4 might be in the region of 20–60 mg;<ref name="CitePiHKAL"/> however high doses such as this might well be associated with toxic side effects, and so extreme caution would be advised.

Society and cultureEdit

PopularityEdit

2C-T-4 is relatively unknown on the black market, but has been sold to a limited extent on the research chemical market.Template:Citation needed

Legal statusEdit

CanadaEdit

As of October 31, 2016, 2C-T-4 is a controlled substance (Schedule III) in Canada.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

ChinaEdit

As of October 2015 2C-T-4 is a controlled substance in China.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

DenmarkEdit

2C-T-4 is added to the list of Schedule B controlled substances.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

SwedenEdit

Sveriges riksdags health ministry Statens folkhälsoinstitut classified 2C-T-4 as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Jul 15, 2007, in their regulation SFS 2007:600 listed as 2,5-dimetoxi-4-isopropyltiofenetylamin (2C-T-4), making it illegal to sell or possess.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

United StatesEdit

As of July 9, 2012, 2C-T-4 is a Schedule I substance in the United States, under the Synthetic Drug Abuse Prevention Act of 2012.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

ReferencesEdit

Template:Reflist

External linksEdit

Template:Psychedelics Template:Serotonin receptor modulators Template:TAAR modulators {{#invoke:Navbox|navbox}}